Rare DNA sequence variants hold important clinical and biological information, but are challenging for existing methods (e.g. PCR, NGS) to profile in an inexpensive, multiplexed, simple-toimplement, and sequence-general way. Here, we present Blocker Displacement Amplification (BDA), a temperature-robust PCR method that selectively amplifies all sequence variants within a roughly 20 nt window by 1000-fold over wildtype sequences, allowing easy detection and quantitation of hundreds of potentials variants originally at ≤0.1% allele frequency. BDA employs a rationally designed competitive hybridization reaction to achieve similar enrichment performance across anneal temperatures ranging from 56 ∘ C to 64 ∘ C. This temperature robustness facilitates multiplexed enrichment of many different variants across the genome, and furthermore enables the use of inexpensive and portable thermocycling instruments for rare DNA variant detection. To show the sequence generality of BDA, we demonstrated enrichment on 156 single-nucleotide variants (SNVs). BDA has been validated on multiple different PCR platforms, DNA polymerases, and sample types including clinical cell-free DNA samples collected from the blood plasma of lung cancer patients. BDA quantitation of mutation allele fraction is generally consistent with deep sequencing results.
Rare DNA sequence variants hold important clinical and biological information, but are challenging for existing methods (e.g. PCR, NGS) to profile in an inexpensive, multiplexed, simple-toimplement, and sequence-general way. Here, we present Blocker Displacement Amplification (BDA), a temperature-robust PCR method that selectively amplifies all sequence variants within a roughly 20 nt window by 1000-fold over wildtype sequences, allowing easy detection and quantitation of hundreds of potentials variants originally at ≤0.1% allele frequency. BDA employs a rationally designed competitive hybridization reaction to achieve similar enrichment performance across anneal temperatures ranging from 56 ∘ C to 64 ∘ C. This temperature robustness facilitates multiplexed enrichment of many different variants across the genome, and furthermore enables the use of inexpensive and portable thermocycling instruments for rare DNA variant detection. To show the sequence generality of BDA, we demonstrated enrichment on 156 single-nucleotide variants (SNVs). BDA has been validated on multiple different PCR platforms, DNA polymerases, and sample types including clinical cell-free DNA samples collected from the blood plasma of lung cancer patients. BDA quantitation of mutation allele fraction is generally consistent with deep sequencing results.
The economical and high-throughput detection and quantitation of nucleic acid sequence variants is a key goal in the road to widespread adoption of precision medicine, wherein optimal individualized treatment is provided to each patient based on his or her unique genetic and disease profile. Profiling rare nucleic acid variants with low allele frequencies, such as cancer mutations in cell-free DNA [1] [2] [3] or drug resistance in pathogen sub-populations [4] [5] [6] , presents a challenge for current molecular diagnostic technologies [7] . Allele-specific PCR methods [8] [9] [10] [11] [12] are difficult to scale to allow highly multiplexed rare variant detection, and deep sequencing approaches [13] [14] [15] are not economical because they waste a large majority of their read capacity on sequencing wildtype templates and amplicons. Sample enrichment to elevate the allele fractions of rare variants can allow economical sequencing-based rare variant profiling, but has been difficult to realize in highly multiplexed settings.
Past demonstrations of DNA variant enrichment employ either selective depletion of wildtype sequences via hybridization [16] [17] [18] [19] or selective PCR amplification of variants [20] [21] [22] [23] . It has been challenging to scale these approach to multiplexed enrichment of many different variants across different loci, because existing methods require that the operational reaction temperature sits in the "Goldilocks" zone of every single blocker or probe. To elaborate, a wildtype sequence at a particular locus may bind to its probe or blocker to form a duplex with melting temperature , and a variant at that locus would form a duplex with melting temperature ( −Δ ); only if the reaction temperature is in the range between these two values is there significant enrichment. Despite more than 40 years of biophysical studies, the melting temperature of a duplex sequence can only be predicted with a standard error of roughly 1.4 ∘ C [25, 26] , corresponding to a 95% confidence interval that spans 5.6 ∘ C. Empirical optimization is impractical in highly multiplexed systems, due to the combinatorially many interactions possible among DNA species that each could influence .
Here, we present a simple method to enrich hundreds of potential DNA sequence variants from multiple genomic loci simultaneously. Simple here denotes both that little to no empirical protocol optimization is needed, and that DNA oligonucleotides employed are unmodified and broadly available. The key enabling innovation is a rationally designed competitive hybridization reaction that enables PCR not only to sensitively recognize and selectively amplify even single nucleotide variations (SNVs) at allele frequencies of 0.1%, but also to do so across a temperature window spanning 8 ∘ C. Our variant allele enrichment method, the Blocker Displacement Amplification (BDA), significantly reduces both the cost and the complexity of profiling rare DNA variants, making genomics analysis more accessible and economical, both for researchers and for clinicians. Compared to other molecular diagnostic technologies used today for detection and quantitation of rare alleles from clinical samples, BDA is unique in simultaneously providing good mutation sensitivity, high mutation multiplexing, fast turnaround, and low reagent and instrument cost (Table 1 ). Furthermore, in contrast to many proof-of-concept works in academic literature showing high mutation sensitivity against one or a few mutations, we here tested 156 single-nucleotide variants to show the sequence generality of BDA enrichment.
Blocker Displacement Amplification (BDA) Design. BDA achieves enrichment through enforcing a differential hybridization yield of the forward Primer P to a wildtype (WT) template vs. to a Variant template, resulting in a difference in per-cycle amplification efficiency ( Fig. 1 ). This differential amplification yield is compounded through multiple cycles of PCR to generate high enrichment factors. Hybridization affinity difference is implemented using a Blocker oligonucleotide B whose binding site on the template overlaps with P's binding site. The simultaneous binding of P and B to the same template molecule is energetically unfavorable; thus, P and B compete in binding through a process of strand displacement [27] . The standard free energy of P displacing B is [12] , NGS [15] , and microarray [24] technologies have improved mutation sensitivity, but BDA is unique in simultaneously providing good mutation sensitivity, high mutation multiplexing, fast turnaround, and low reagent and instrument cost. designed to be marginally positive (thermodynamically unfavorable) in the case of a WT template (Δ ∘ WT ), but will be negative for a Variant template due to the mismatch bubble or bulge formed between B and the Variant template.
The values of Δ ∘ WT and Δ ∘ Var for a given set sequences are only weakly dependent on the temperature of the PCR anneal step, because temperature affects the hybridization stability of both P and B to the template similarly. The competitive hybridization reaction pitting P versus B operates based on a similar principle as the toehold probe [27, 28] , which was shown both theoretically and experimentally to exhibit a large affinity difference between SNVs across a large range of temperatures and salinities at equilibrium. However, rapidly changing temperatures and the enzymatic extension of primers in a PCR reaction prevents the solution from attaining equilibrium, necessitating the development of a different, kinetics-driven model for simulating and analyzing BDA behavior. Our model provides design guidelines for maximizing enrichment performance, such as the stoichiometry of B and P. Details of our model are described in Section S2.
In order for BDA to act as an enrichment assay, the sequences of the amplicon must faithfully correspond to the sequences of variant templates originally existing in solution. Consequently, P must bind a conserved sequence upstream of the loci with potential sequence variations (because amplicons always bear the sequence of the primer, and any variations in the primer-binding region of the template would be overwritten). The enrichment region of a BDA system thus corresponds to the nucleotides to which the Blocker uniquely binds; templates with sequence variations within the enrichment region are preferentially amplified. The exact length of this enrichment region depends on the sequence in this region, but for the experiments shown here, this length ranges between 12 and 30 nt.
Any of a number of 3 ′ modifications could be used to effectively prevent the Blocker from being extended by the DNA polymerase during PCR; examples include a minor groove binder [12] , an inverted DNA nucleotide, and a 3-carbon spacer [29] . In this manuscript, however, we opted for a simpler approach by adding 4 unmodified nucleotides at the 3 ′ end of the Blocker that do not pair with the template. For DNA polymerases lacking 3 ′ to 5 ′ exonuclease activity, this 3 ′ "terminator" sequence effectively blocks amplification for all sequences that we tested. We opted for this approach both because such unmodified oligonucleotides are significantly less expensive than functionalized counterparts, and because the thermodynamics of their hybridization are better understood. Although only 2 nt of terminator sequence are needed to suppress Blocker extension, we chose to use 4 nt terminator sequences to account for the possibility of potential Variant templates that happen to match one of the terminator sequence nucleotides, and to account for possible oligonucleotide synthesis errors.
Results
Non-pathogenic SNP Results on Genomic DNA. To quantitate the fold-enrichment of BDA on a representative set of SNVs, we first performed enrichment of non-pathogenic SNPs from human genomic DNA (gDNA). NA18537 and NA18562 are genomic DNA samples extracted from two cell lines as part of the 1000 Genomes Project [30], and have wellcharacterized genotype information for many non-pathogenic SNPs. We generated gDNA samples with a variety of variant allele fractions (VAFs) by mixing the NA18537 and NA18562 samples at different ratios. Fig. 2abc shows the design and performance of a BDA design for detecting the rs3789806 C>G SNP. The sample with 0.01% VAF can be clearly distinguished from that with 0% VAF, indicating that more than 10,000× SNV enrichment is achieved. The Sanger sequencing results of amplicons from BDA enrichment of the 0.1% VAF sample ( Fig. 2d ) verify that BDA functions as an enrichment method, wherein the amplicons reflect the sequences of the original Variant templates. The regression line between the cycle threshold (Ct) and the VAF has slope of 3.45, indicating that PCR amplification of the variant template occurs at near 100% efficiency. This conclusion is supported by the observation that the 100% VAF sample exhibits at similar Ct in PCR reactions with and without the Blocker (see Section S3).
BDA is a sequence-general method that effectively enriches all SNVs regardless of the nucleotide identities of the Vari- 26 28 ant and WT. Fig. 2e summarizes the qPCR results for 24 separate BDA systems, representing two instances of each of the 12 possible SNV/WT nucleotide pairs; for a large majority of WT/SNV pairs, the median enrichment observed was greater than 1000. The results in Fig. 2e are for preliminary BDA designs that were not subjected to empirical optimization; our later experiments ( Fig. 4d ) suggest that some Primer/Blocker sequence adjustments may lead to even better enrichment performance.
Temperature Robustness. An important and novel distinguishing feature of BDA is the broad temperature range over which it effectively enriches variants. Fig. 3ab shows the enrichment performance of the BDA system across anneal/extend step temperatures ranging between 55 and 65 ∘ C. The Ct values for 1% VAF and 0% VAF samples maintain a difference of more than 10 cycles for anneal/extend temperatures of 56 through 64 ∘ C. Below 56 ∘ C, DNA polymerase activity decreases, resulting in poor amplification; above 64 ∘ C, 
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Reverse Primer Sequence Blocker Stoichiometry the hybridization of the primer to either template becomes unstable, also resulting in poor amplification. As a contrast to BDA's temperature robustness, we also tested enrichment PCR on the rs3789806 SNP using LNA clamp oligonucleotides at a variety of temperatures ( Fig. 3c ; see Section S5). The LNA clamp provided high amplification yield and significant discrimination between 1% and 0% VAF only at anneal/extend temperatures of 56 to 57 ∘ C. Our expectation is that similar temperature sensitivities would be observed for other existing PCR enrichment methods [20, 23] [41].
BDA temperature robustness is sequence-generic; Fig. 3d shows the observed Ct values for 6 WT/Variant pairs at 100%, 1%, and 0% VAF. The Ct values of triplicate 100% VAF and 1% VAF samples are generally consistent across all temperatures tested. Some variability observed in the Ct of the 0% VAF sample is believed to be primarily due to the stochastic nature of the early cycles of PCR, specifically in (1) enzyme misincorporation errors and (2) WT amplification yields. These hypotheses are supported by the observation that larger gDNA input quantities result in smaller variability in 0% VAF Ct values; at 4 ng and 200 ng gDNA input, the standard deviation of 96 BDA reactions with 0% VAF were observed to be 4.02 and 0.48 cycles, respectively (Section S4).
The broad temperature robustness of BDA manifests as a strong advantage both in the design and operation of multi-plexed allele enrichment systems, and in the use of portable and inexpensive thermocycling equipment to detect and enrich sequence variants. Fig. 3e shows polyacrylamide gel electrophoresis results of using a 3-plex BDA system on the MiniPCR, an instrument with dimensions of roughly 5 cm × 13 cm × 10cm and a commercially available retail price of $650 [31, 32] . BDA may thus facilitate point of care or field-use nucleic acid testing, for applications such as cancer recurrence monitoring in a primary care physician's office. The fact that the BDA Primer and Blocker are unmodified DNA oligonucleotides means that reagents are significantly less expensive than modified or functionalized alternatives, rendering BDA desirable for testing in resource-limited settings (e.g. for infectious disease antibiotic resistance diagnostics).
To demonstrate higher multiplexing capability as well as to observe amplification dynamics, we next performed 9-plex BDA on a standard Biorad CFX 96 instrument. The Ct values observed are consistent with expectations based on single-plex results, and the decrease of primer and blocker concentrations necessary for allowing 9-plex amplification does not appear to significantly affect Ct values when cycle times are lengthened to compensate (Fig. 3f) . Importantly, the multiplex enrichment experiments summarized in Fig. 3ef represent our first-try designs, and did not undergo any empirical optimization. We believe that significantly higher multiplexed allele enrichment can be achieved with BDA; however, methods of readout more sensitive and multiplexed than traditional qPCR instruments are needed to fully capture the value of multiplexed BDA.
Model vs. Experiments. We model the BDA reaction in two parts: (1) a mass-action kinetic simulation of the hybridization and enzyme elongation reactions at each anneal/extend step to calculate the per-step amplification yield for the WT and Variant templates, and (2) a discrete simulation of each PCR cycle using the amplification yields from the previous step. Where possible, we used literature-reported rate constants and standard free energies; two parameter values were estimated ad hoc. The purpose of this model is to understand the effects of various design parameters on the enrichment performance of BDA; accurate quantitative match between simulation and experimental traces is secondary (Fig. 4a ). Deviations between model and experimental results likely reflect both the simplicity of the model and the inaccuracy of literature reported thermodynamics parameters [25, 33] .
Our model suggests that ΔΔ ∘ is a key parameter that sets the upper limit for the achievable enrichment by BDA. ΔΔ ∘ denotes the difference in the standard free energy of hybridization of the Blocker binding to the WT as compared to binding to the Variant, and is primarily dependent on the sequence identities of the WT and Variant alleles. At 60 ∘ C and typical PCR buffer conditions, ΔΔ ∘ values range between 0.8 kcal/mol and 5 kcal/mol. The model suggests that larger ΔΔ ∘ results in larger ΔCt values, with saturation at roughly 3 kcal/mol. Thus, some Variant/WT pairs with smaller ΔΔ ∘ will exhibit lower enrichment by BDA due to their sequence identities.
For enrichment of a specific Variant sequence, many BDA designs will yield good enrichment, as long as design principles are followed (Fig. 4d ). This flexibility further facilitates the design of highly multiplexed BDA systems, because specific BDA designs for enriching different loci may be incompatible with one another (e.g. tendency to form primer dimers).
Hotspot Multiplexing. BDA enriches all Variants with sequence differing from the WT in the enrichment region. For a typical 20 nt enrichment region, 60 SNVs can be simultaneously enriched by a single BDA system, albeit with differing fold-enrichment because of varying ΔΔ ∘ values. In this regard, BDA and other enrichment PCR techniques are significantly superior to allele-specific PCR (e.g. ARMS) approaches -each plex of BDA is the equivalent of a 60-plex ARMS. To rigorously demonstrate that BDA does enrich all potential variants in the enrichment region, we systematically designed 2 sets of synthetic DNA templates bearing SNVs, corresponding to all SNVs in a 18 nt enrichment region on chromosome 5 and a 21 nt enrichment region on chromosome 11 (Fig. 5a ). The experimentally observed distribution of ΔCt values for these SNVs range between 7 and 14, with mean and median both at roughly 10.5 (corresponding to over 1000-fold enrichment). Note that the same BDA primer/blocker system was used to enrich all 54 SNVs in the left panel, and another BDA system was used to enrich all 63 SNVs in the right panel. In applications where BDA is used to detect/quantitate a suspected known mutation ( Fig. 2e) , significantly higher ΔCt is achieved because the BDA system can be designed to either the forward strand or the reverse strand, depending on which exhibits the larger ΔΔ ∘ value (Fig. 4b , see also Section S8).
Hotspot multiplexing is important for a variety of molecular diagnostics applications. For example, codons 12 and 13 in the KRAS oncogene is a hotspot region in which 12 different non-synonymous point mutations have been observed. Mutation status of KRAS can information clinical treatment; colorectal cancer patients are resistant and not recommended to be prescribed cetuximab.
We designed a BDA system to query variants in codons 12 and 13 of the KRAS gene. To test the BDA system, we diluted 5 reference cell line gDNA samples with different KRAS mutations (Horizon Discovery) with WT cell line DNA to generate 0.1% VAF samples. Sanger sequencing of the amplicons after BDA (Fig. 5b ) confirms that amplicon sequence identity matches that of the original sample mutations. To unambiguously detect a specific Variant of interest, two separate BDA reactions should be run: one with a standard WT Blocker, and one containing both the WT Blocker and a Blocker to the Variant of interest (Fig. 5c ). Significant amplification (low Ct) of a sample with the second BDA reaction indicates that the sample contains an incidental variant other than the Variant of interest.
Enhancing Enrichment. The allele enrichment achieved by BDA is limited by two factors: (1) DNA polymerase nucleotide misincorporation events that create de novo Variants subsequently enriched by BDA [35] , and (2) imperfect suppression of WT template amplification by the Blocker. Limitation (1) can be mitigated through the use of highfidelity DNA polymerases with 3 ′ to 5 ′ proofreading activity (Fig. 5d ), and (2) can be mitigated through the use of a second Blocker for the reverse primer ( Fig. 5e ). For different Variant/WT pairs, either (1) or (2) may be dominant; thus, addressing each of these two problems results in improved BDA performance for a subset of Variant/WT sequence pairs. Judicious application of these two approaches allows BDA enrichment to be enhanced for a large fraction of, if not all, Variant/WT pairs.
Clinical Cell-Free DNA Analysis.
Cell-free DNA (cfDNA) consists of short (approx. 160 nt) double-stranded DNA molecules present in blood plasma at roughly 5 to 20 ng/mL [1] . Cancer-specific mutations in cfDNA can be used for noninvasive therapy guidance or recurrence monitoring [2, 3, 38] , and even holds potential as cancer early detection biomarkers [39] . Fig. 6 shows the BDA qPCR results for the analysis of cell-free DNA from the blood plasma of 7 lung cancer patients, collected between Jan 2013 and Nov 2014 (see also Section S9). Informed consent was obtained from all subjects. As a comparison, the cfDNA mutations were also profiled by deep sequencing using molecular lineage tags to suppress sequencing and PCR errors via a modified version of the technique presented in ref. [36] . There is general agreement on mutant VAF between the BDA qPCR and the deep sequencing methods; differences observed may be due to unequal distribution of mutant cfDNA during sample splitting (sample 2), or due to differences in mutation VAF based on different length cfDNA fragments (sample 5). [36, 37] . The observed difference in some samples between deep sequencing and BDA may be due to unequal partitioning of rare mutation-bearing cfDNA molecules at near the Poisson limit.
For example, tumor-derived cfDNA fragments are typically shorter than normal cfDNA, so the choice of amplicon length may impact the observed allele frequency.
Discussion
BDA overcomes the temperature sensitivity that limit all existing PCR enrichment methods through a rationally designed competitive hybridization reaction. This temperature robustness translates into practical advantages for molecular diagnostics and genomics research in at least two ways: facilitating the highly multiplexed enrichment of many SNVs, and enabling the use of more portable and economical PCR instruments with lower temperature accuracy and uniformity. BDA does not rely on expensive functionalized DNA oligonucleotides, is broadly compatible with many enzymes, and is tolerant to instrument temperature inaccuracies and non-uniformity; consequently, BDA is highly economical and accessible to clinicians and researchers. Systematic experimental validation of BDA enrichment on 156 different SNVs, and on a variety of samples ranging from synthetic templates to cell line genomic DNA to clinical blood samples, shows the robustness of BDA as a rare variant enrichment and detection method.
An immediate area of clinical application for BDA technology is noninvasive cancer recurrence monitoring based on cfDNA. NGS-based solutions for analyzing cfDNA DNA are too costly to be repeatedly and regularly applied, while lowmultiplex PCR methods are insufficient for high clinical sensitivity. In this manuscript, we demonstrated multiplex BDA targeting 9 different genomic regions within the same reaction; simultaneously, we showed that each BDA system is capable of enriching and detection 50+ variants. Together, these indicate that roughly 500 different SNVs can be detected at roughly 0.1% allelic frequency in a single low-cost and rapid reaction. Additional development and optimization of the BDA technique could potentially further extend the number of mutations detected and enriched to over 1000, suggesting a rare variant discovery as another potential application for BDA.
The fold-enrichment achieved for SNVs using the basic BDA implementation (lacking high fidelity enzyme and dual blocking) was observed to be between approximately 300 and 30,000, varying based on SNV and WT sequences. This performance could be improved through empirical optimization, as the DNA hybridization thermodynamics parameters we used for designing BDA systems are known to be imperfect [25] . In settings where open-tube procedures are allowed (e.g. NGS library preparation), multiple rounds of BDA enrichment followed by dilution could result in theoretically unlimited rare mutation sensitivity.
